The Board of Directors of UCrest Berhad ("UCrest" or "the Company") is pleased to announce that the Company has been granted its first patent in Taiwan for its flagship product iMedic™, an Artificial Intelligence (AI)-powered digital health platform.

The patent granted covers AI-driven health management and its methods for telemedicine services, marking a major achievement in UCrest’s intellectual property journey and reinforcing its leadership in the global digital healthcare industry. The patent protects the Company’s innovations in AI-powered diagnostics, personalised health analytics, and remote patient management, strengthening iMedic™’s position as a leading platform connecting patients, doctors, and healthcare institutions seamlessly across borders.

Pioneered in digital health, the core technologies of iMedic™ are powered by Artificial Intelligence (AI), Internet of Things (IoT), Blockchain, and data analytics integrated with a robust Electronic Medical Records (EMR) system. This combination of intelligent connectivity and secure data infrastructure enables iMedic™ to deliver highly personalised healthcare, continuous monitoring, and predictive analytics for preventive care and chronic disease management.

The Company will continue to innovate and lead the digital health industry through advanced research and development. UCrest expects to file many more patents in the near future as it further expands the technological capabilities and applications of its iMedic™ platform.

This patent approval not only enhances UCrest’s competitive edge in digital health innovation but also reinforces its value proposition to global partners, investors, and healthcare institutions as it continues to expand its international footprint.

This announcement is dated 14 October 2025.